Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
24.24
-0.16 (-0.66%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Palvella Therapeutics Employees
Palvella Therapeutics had 14 employees as of December 31, 2024.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,245,286
Market Cap
268.42M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
PVLA News
- 8 days ago - Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology - GlobeNewsWire
- 17 days ago - Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology - GlobeNewsWire
- 19 days ago - Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 - GlobeNewsWire
- 7 weeks ago - Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old - GlobeNewsWire
- 4 months ago - Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million - GlobeNewsWire